TNF and cancer: Considering the major role of inflammation in the induction of cardiac dysfunction in cancer patients, various studies were conducted to target pro-inflammatory markers such as the IL-1α antagonist (MABp1) [123], IL-1β inhibitor (Canakinumab) [124], IL1β receptor antagonist (Anakinra), TNFα antagonist (Infliximab and Etanercept) [125], and IL-6 antagonist (Clazakinumab) [126].